NPPA issued a notification regarding fixation of the retail price of Sitagliptin Phosphate Monohydrate IP Eq. to Sitagliptin 100 mg + Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP 500 mg (As Extended Release) for M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Blue Cross Laboratories Pvt. Ltd. (Marketer)

Mar 06, 2025 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific ComplianceThe National Pharmaceutical Pricing Authority (NPPA) on March 05, 2025, issued a notification regarding fixation of the retail price of Sitagliptin Phosphate Monohydrate IP Eq. to Sitagliptin 100 mg + Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP 500 mg (As Extended Release) for M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Blue Cross Laboratories Pvt. Ltd. (Marketer).

The following has been stated: -

•For each film-coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP Eq. to Sitagliptin 100 mg + Dapagliflozin Propanediol USP Eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP 500 mg (As Extended Release) for M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Blue Cross Laboratories Pvt. Ltd. (Marketer) the retail price is 17.90 (Rs).

The detailed notification is given in the document below.


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT